Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 181 placebo-controlled phase 2 trial in moderate to severe ulcerative colitis
NL-OMON39233Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing AMG 181 with Placebo (2 arms). Primary endpoint: Remission at week 8. Started Feb 2013; status: active, not recruiting.
02
Drugs
abrilumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON39233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39233.